Iciency Virus Replication. US: Bristol Myers Squibb Co; 2012. BAY 11-7083 cost WO2012/033735 A1. 31. De
Iciency Virus Replication. US: Bristol Myers Squibb Co; 2012. WO2012/033735 A1. 31. De La Rosa MA, Haidar SN, Johns BA, Velthuisen EJ: Isoquinoline Compounds and Methods for Treating HIV. US: Glaxo Smithkline LLC; 2012. WO2012/102985 A1. 32. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R: Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses. Laboratoire Biodim, FR; 2012. WO2012/137181 A1. 33. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R: Inhibitors of viral replication, their process of preparation and their therapeutical uses. Laboratoire Biodim FR 2012. WO2012/140243 A1. 34. Hattori K, Kurihara N, Iwaki T, Inoue T, Akiyama T, Hasegawa Y: HIV Replication Inhibitor. Shionogi Co., JP; 2013. WO2013/002357 A1. 35. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26866270 S, Smets W, Chaltin P, Westby M, Debyser Z, Pickford C: Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 2012, 56:4365?374. 36. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung M, Samuel D, Novikov N, Xu Y, et al: New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 2012, 287:21189?1203. 37. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SF, Engelman A, et al: Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012, 287:16801?6811. 38. Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F: Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen 2012, 17:618?28. 39. Christ F, Debyser Z: The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 2013, 435:102?09. 40. Wang H, Jurado KA, Wu X, Shun MC, Li X, Ferris AL, Smith SJ, Patel PA, Fuchs JR, Cherepanov P, et al: HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25679764 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res 2012, 40:11518?1530. 41. Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, et al: The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2013, 288:15813?5820. 42. Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, et al: LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 2013, 10:57. 43. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W, Ballandras-Colas A, Patel PA, Fuchs JR, et al: Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci USA 2013, 110:8690?695. 44. Yant S, Tsai L, O’Sullivan C, Cihlar T, Balakrishnan M: Non-Catalytic Site Integrase Inhibitors Target the Integrase Domain During Virus Production and Induce a Reverse Transcription Block, Conference on Retroviruses and Opportunistic Infections. Gilead Sciences: Atlanta, GA, USA; 2013. 45. Balakrishnan M, Yant SR, Tsai L, O’Sullivan C, Bam RA, Tsai A, Niedziela-Majka A, Stray KM, Sakowicz R, Cihlar T: Non-catalytic site HIV-1 integr.
